Multimodal Magnetic Resonance Imaging in Cardiovascular Diseases

What this Trial Is About

Researchers are evaluating the clinical usefulness of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with various cardiovascular diseases (CVD), including ischemic heart disease, cardiomyopathy, myocarditis, and valvular diseases. This observational study aims to improve early detection, accurate diagnosis, risk assessment, and outcome prediction by establishing a standardized imaging assessment system. It focuses on comparing the diagnostic and prognostic value of advanced CMR techniques across a broad range of heart conditions. Participants will undergo a comprehensive "one-stop" multi-modal CMR scan using 3.0T MRI scanners. This includes Cine imaging, T1/T2 mapping, Late Gadolinium Enhancement, first-pass perfusion, and 4D flow sequences to evaluate heart structure, function, tissue characteristics, and blood flow dynamics. The study plans to enroll about 2,000 patients who are clinically suspected or confirmed to have CVD and will follow them over time to collect imaging data and clinical outcomes. During the study, participants will receive baseline multi-modal CMR scans as part of their routine clinical care. Researchers will collect detailed imaging parameters at the time of the scan and track major adverse cardiovascular events (MACE) during long-term follow-up for up to three years. The primary outcome is to assess the diagnostic accuracy of the CMR parameters, while secondary outcomes include correlations between imaging and clinical indicators. Safety, adherence, and quality of imaging will be monitored throughout the study period, which is expected to last until the end of 2028.

Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease